respiratory syncytial virus

RSV respiratory syncytial virus
Biotech

Vicebio hauls in $100M series B to push RSV shot through phase 1

The respiratory syncytial virus space may have filled up over the past year, but that isn’t deterring Vicebio or its investors.
James Waldron Sep 23, 2024 3:00am
Sketch of lungs

Merck’s mAB prevents RSV in infants, teeing up talks with FDA

Jul 23, 2024 8:18am
vaccine diversity flu covid shot needle

Moderna's RSV shot efficacy wanes faster than GSK's Arexvy

Feb 9, 2024 2:44pm
declining money logos to indicate losing money

Veru needs cash for fresh trial of respiratory distress drug

Feb 8, 2024 10:45am
RSV virus

AstraZeneca enters RSV vaccine race with $800M Icosavax buy

Dec 12, 2023 5:19am
Bancel

After initial stumbles, Moderna gets clean win for mRNA flu shot

Sep 13, 2023 6:30am